A Rare Case of Basal Cell Adenocarcinoma of Parotid Gland with Intracranial Extension

AbstractBasal cell adenocarcinoma (BCAC) is a rare tumour entity. Despite its tendency to be infiltrative and destructive tumour with propensity to recur, it rarely metastasizes and long-term outcome following surgery is favourable. This paper presents a 42-year-old male with residual BCAC of parotid gland that had extended into infratemporal fossa and intracranial. The important aspect of this case is the rarity occurrence of BCAC of parotid with intracranial extension and its surgical approaches to achieve tumour clearance.
Source: Indian Journal of Otolaryngology and Head and Neck Surgery - Category: ENT & OMF Source Type: research

Related Links:

Cancer Gene Therapy, Published online: 23 September 2019; doi:10.1038/s41417-019-0135-5SOX17, β-catenin and CyclinD1 expression in the endometrioid adenocarcinoma and influence of 5-AZA on expression
Source: Cancer Gene Therapy - Category: Cancer & Oncology Authors: Source Type: research
Publication date: Available online 21 September 2019Source: Pathology - Research and PracticeAuthor(s): Rahul Mannan, Alexander S. Taylor, Daniel E. Spratt, Arul M. Chinnaiyan, Jeffrey S. Montgomery, Noah A. Brown, Rohit MehraAbstractBladder cancer continues to be a source of disease burden worldwide. In patients with a long-standing history of prostate cancer, distinguishing between new/independent and synchronous poorly differentiated urothelial carcinoma (UCA) and residual/recurrent high grade/poorly differentiated prostatic adenocarcinoma or prostatic adenocarcinoma with therapy-related changes can be diagnostically an...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Publication date: Available online 20 September 2019Source: Seminars in Cancer BiologyAuthor(s): Trista K. Hinz, Lynn E. HeasleyAbstractMalignant pleural mesothelioma (MPM) is a rare, yet lethal asbestos-induced cancer and despite marked efforts to reduce occupational exposure, the incidence has not yet significantly declined. Since 2003, combined treatment with a platinum-based agent and pemetrexed has been the first-line therapy and no effective or approved second-line treatments have emerged. The seemingly slow advance in developing new MPM treatments does not appear to be related to a low level of clinical and pre-clin...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Cancers, Vol. 11, Pages 1411: Programmed Death–Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC Cancers doi: 10.3390/cancers11101411 Authors: Julien Ancel Philippe Birembaut Maxime Dewolf Anne Durlach Béatrice Nawrocki-Raby Véronique Dalstein Gonzague Delepine Silvia Blacher Gaëtan Deslée Christine Gilles Myriam Polette In non-metastatic non-small-cell lung cancer (NSCLC), outcomes remain poor. Adjuvant chemotherapies provide a limited improvement in disease-free survival. Recent exploratory studies on early-stage NSCLC show that immunotherapy ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Publication date: September 2019Source: European Urology Supplements, Volume 18, Issue 6Author(s): S. Cakmak, E. Koseoglu, K. Tarim, A.E. Canda, M.C. Kiremit, Y. Kordan, A. Armutlu, D. Ertoy, M.D. Balbay, T. Esen
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
Publication date: Available online 20 September 2019Source: International Journal of Surgery Case ReportsAuthor(s): Shin Takayama, Kaishi Satomi, Masayuki Yoshida, Chikashi Watase, Takeshi Murata, Sho Shiino, Kenjiro Jimbo, Akihiko SutoABSTRACTINTRODUCTIONSpontaneous regression of a malignant tumor is defined as “the partial or complete disappearance of a malignant tumor in the absence of any treatment.” Herein, we report a case of occult breast cancer with axillary lymph node metastasis that showed spontaneous tumor regression based on the histopathological findings.PRESENTATION OF THE CASEA 67-year-old woman ...
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
Publication date: Available online 21 September 2019Source: Cirugía Española (English Edition)Author(s): Alexis Luna Aufroy, Salvador Navarro SotoAbstractPreoperative clinical staging is critical to select those patients whose disease is localized and may benefit from surgery with curative intent. Ideally, such staging should predict tumor invasion, lymphatic involvement and distant metastases. With the cTNM, we are able to select patients who could benefit from endoscopic resection, radical surgery or less radical treatment in patients with distant metastasis. The initial diagnosis of adenocarcinomas of the ...
Source: Cirugia Espanola - Category: Surgery Source Type: research
Authors: Kamyabi N, Bernard V, Maitra A Abstract Introduction: Pancreatic ductal adenocarcinoma (PDAC) is a disease of near uniform lethality. Invasive tissue biopsies of primary or metastatic lesions remain the gold standard for diagnosis, but repeated sampling is infeasible. Non-invasive liquid biopsies, which better represent the heterogeneity of PDAC, offer new opportunities for early diagnosis during surveillance in high-risk cohorts, and for the longitudinal analysis of tumor evolution and progression in patients on therapy. In particular, liquid biopsies can capture tumor-associated components, such as circu...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Conclusions: Chromosomal alterations were frequently identified in both PDAC and IPMN with similar patterns. CEP18 gain and 17p and 18q deletions might be involved in the later stages of PDAC tumorigenesis. Chromosome 17p and 18q deletions might be excellent diagnostic markers. PMID: 31533396 [PubMed - as supplied by publisher]
Source: Gut and Liver - Category: Gastroenterology Tags: Gut Liver Source Type: research
Authors: Hotta T, Okimoto T, Hamaguchi M, Tsubata Y, Isobe T Abstract A 40-year-old Japanese man with advanced pulmonary adenocarcinoma harboring anaplastic lymphoma kinase (ALK)-rearranged was administered the selective ALK inhibitor ceritinib as a third-line treatment and continued treatment for nine months. After fourth-line treatment, we performed rechallenge with ceritinib as a fifth-line treatment. On day 54 after rechallenge, the patient developed acutely deteriorating dyspnea. Chest computed tomography showed extensive ground-glass opacities. We diagnosed him with ceritinib-induced interstitial lung disease...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
More News: Adenocarcinoma | ENT & OMF